Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction

Original Research

Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction

Journal: Neurol Ther (2021) 10:1015–1028

Timeline: Received: June 18, 2021 / Accepted: August 25, 2021 / Published Online: September 13, 2021

Authors: Huei-Chun Liu, Hsin-Hsien Chen, Chia-Shin Ho, Jui-Feng Chang, Chia-Chun Lin, Ming-Jang Chiu, Ta-Fu Chen, Chaur-Jong Hu, Sui-Hing Yan, Yu Sun, Shieh-Yueh Yang

Neurology and Therapy Alzheimer's Disease Immunomagnetic Reduction (IMR) Plasma Biomarkers

Article Citation

Huei-Chun Liu, Hsin-Hsien Chen, Chia-Shin Ho, Jui-Feng Chang, Chia-Chun Lin, Ming-Jang Chiu, Ta-Fu Chen, Chaur-Jong Hu, Sui-Hing Yan, Yu Sun, Shieh-Yueh Yang. (2021).
Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction.
Neurol Ther, 10: 1015–1028.

Digital Object Identifier (DOI):
https://doi.org/10.1007/s40120-021-00280-1

Immunomagnetic Reduction (IMR)

Utilizing high-precision IMR technology to evaluate sample replication requirements and define standard assay protocols for neurodegenerative blood assessments.

Clinical Assay Optimization

Determining the statistical minimum of analytical test runs necessary to reliably detect and quantify low-abundance plasma biomarkers linked to Alzheimer's pathology.

Neurology and Therapy Literature Archive Overview